Anti-aging NMN three-layer sustained release tablet and preparation method thereof
By designing the three-layer sustained-release tablet structure and using the pre-pressure preparation method, the problem of the rapid release of NMN sustained-release tablets is solved, and the sustained-release behavior is achieved for 24 hours and the improvement of bioavailability, which is suitable for once a day.
Patent Information
- Application Number
- CN202411065056.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
Existing NMN sustained-release tablets are released too quickly in the body, resulting in low bioavailability, unable to meet the demand for once a day, and it is difficult to control the sudden release of the drug, affecting the continuous and slow release of the drug.
A three-layer sustained-release tablet structure was designed. The drug-containing layer consists of NMN, sustained-release material and filler. The upper and lower blank layers contain sustained-release material, filler and lubricant. The pre-pressing preparation method ensures the sustained-release material. Even distribution and slow release of drugs.
The sustained release behavior lasts for 24 hours, reduces early sudden release, improves bioavailability, ensures that the drug maintains blood drug concentration in the body for a long time, and is suitable for once a day.
Smart Images

Figure CN118975995A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an anti-aging NMN three-layer sustained-release tablet and a preparation method thereof, belonging to the technical field of sustained-release drug delivery systems. Background Art
[0002] β-Nicotinamide mononucleotide (NMN) is a coenzyme I (NAD + ) is an important intermediate substance in the synthesis of NMN, and has good therapeutic effects in the treatment of cardiovascular and cerebrovascular diseases, neurodegenerative diseases, and delaying aging. As an aging component, the recommended dosage for people of different ages is different, 300 mg / day for those over 40 years old and 600 mg / day for those over 60 years old. NMN is easily saturated when absorbed orally, and its bioavailability is not high. It needs to be taken 2-3 times a day, morning and evening, and it is easy to miss a dose.
[0003] Based on the above reasons, slowly releasing drugs in the body is a starting point for solving current problems.
[0004] The inventor team found some related patent applications after searching, such as:
[0005] A nicotinamide mononucleotide sustained-release enteric-coated orally disintegrating tablet and a preparation method thereof (CN202011041898.9). The drug is not released in the stomach but only after reaching the intestine, and takes effect slowly.
[0006] A sustained-release tablet suitable for β-nicotinamide mononucleotide (CN202311270380.6). The sustained-release tablet has a 12h sustained-release effect, a 4h cumulative release percentage of 45%, and an 8h cumulative release percentage of 79%. The sustained-release tablet disclosed in the invention is a single-layer structure. The sustained-release tablet releases too quickly in 4h, and the human body absorbs easily, thereby affecting the bioavailability. And the sustained-release behavior cannot last for 24h, which cannot meet the need of once-daily dosing.
[0007] A β-nicotinamide mononucleotide sustained-release tablet (CN202110196720.X). The sustained-release tablet has an 8-hour sustained-release effect, a cumulative release of 83.91% in 6 hours, and a cumulative release rate of 96.54% in 8 hours. The sustained-release tablet disclosed in the invention is a single-layer structure. The sustained-release tablet releases too quickly in 6 hours, and the human body is easily saturated with absorption, thereby affecting the bioavailability. And the sustained-release behavior cannot last for 24 hours, which cannot meet the need of once-daily dosing.
[0008] NMN is a water-soluble small molecule drug with fast dissolution and diffusion rates. When preparing large-dose sustained-release tablets, it is technically difficult to reduce the initial burst release (avoiding too high a release percentage in 4h or 6h). NMN is easily saturated after oral absorption, resulting in low bioavailability. Therefore, it is necessary to control the initial burst release and maintain a continuous slow release of large-dose sustained-release tablets. According to existing research and literature reports, current technology has not really solved this problem. Summary of the invention
[0009] In order to solve the above problems, the present invention discloses an anti-aging NMN three-layer sustained-release tablet and a preparation method thereof, and designs NMN into a sustained-release drug delivery system so that the drug is slowly released in the body, which can maintain the blood drug concentration for a long time, improve the bioavailability of NMN, and improve the patient's compliance with use. The specific technical scheme is as follows:
[0010] An anti-aging NMN three-layer sustained-release tablet comprises a sheet-shaped drug-containing layer, wherein one side surface of the drug-containing layer is an upper surface, and the other side surface is a lower surface, the upper surface of the drug-containing layer is fully covered by pressure bonding with an upper blank layer, and the lower surface of the drug-containing layer is fully covered by pressure bonding with a lower blank layer, the upper blank layer and the lower blank layer have the same components, specifications and properties, the upper blank layer / lower blank layer contains a sustained-release material, a filler and a lubricant; the mass percentage of the sustained-release material in the upper blank layer / lower blank layer is 50%-70%,
[0011] The drug-containing layer contains NMN, sustained-release material and filler; the mass percentage of NMN in the drug-containing layer is 40%-60%, and the mass percentage of sustained-release material in the drug-containing layer is 20%-40%;
[0012] The sustained-release material is one or more of HPMC, EC, and CMC-Na, the filler is one or more of MCC, starch, and dextrin, and the lubricant is one or more of magnesium stearate or micro-powder silica gel.
[0013] Furthermore, the mass percentage of the sustained-release material in the upper blank layer / lower blank layer is 60%.
[0014] Furthermore, the mass percentage of NMN in the drug-containing layer is 50%.
[0015] Furthermore, the mass percentage of the sustained-release material in the drug-containing layer is 30%.
[0016] Furthermore, the sustained-release material is HPMC.
[0017] Furthermore, the sustained-release material is HPMC K4M and HPMC K100M.
[0018] Furthermore, the filler is MCC.
[0019] Furthermore, the diameters of the upper blank layer, the lower blank layer and the drug-containing layer are all 12.0 mm, and the hardness is 50-200N; the upper blank layer / lower blank layer weighs 50-200 mg, and the middle drug-containing layer weighs 300-500 mg.
[0020] Furthermore, the upper blank layer / lower blank layer weighs 150 mg; and the drug-containing layer weighs 400 mg.
[0021] The method for manufacturing the above-mentioned anti-aging NMN three-layer sustained-release tablet comprises the following steps:
[0022] Step (1) mixing the ingredients of the lower blank layer and pre-pressing the lower blank layer;
[0023] Step (2) mixing the prescription ingredients of the drug-containing layer, filling them on the lower blank layer, and pre-pressing them to obtain a double-layer tablet;
[0024] Step (3) The prescription ingredients of the upper blank layer are mixed evenly, and filled onto the blank surface of the drug-containing layer of the pre-compressed double-layer tablet obtained in step (2) to obtain a three-layer tablet.
[0025] The beneficial effects of the present invention are:
[0026] (1) The sustained-release behavior of the three-layer sustained-release tablet of the present invention can last for 24 hours, achieving a dosing frequency of once a day.
[0027] (2) After oral administration of the three-layer sustained-release tablets of the present invention, there is no obvious burst release in the early stage, the cumulative release percentage in 4 hours does not exceed 25%, the cumulative release percentage in 8 hours does not exceed 50%, and the release percentage in 12 hours does not exceed 75%. As a water-soluble small molecule drug, NMN has a very fast dissolution and diffusion rate. When preparing large-dose NMN sustained-release tablets, early burst release is prone to occur (the release percentage in 4 hours or 6 hours is too high), and the oral absorption of NMN is easily saturated, resulting in low bioavailability. Therefore, it is necessary to control the early burst release of NMN sustained-release tablets, and existing public research and literature have not solved this problem.
[0028] The invention discloses a method for preparing an NMN sustained-release tablet with a three-layer structure, which adopts a pre-compression method, has simple equipment and low production cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 is a three-layer sustained-release tablet of the present invention.
[0030] List of reference numerals: 1—upper blank layer, 2—drug-containing layer, 3—lower blank layer.
[0031] Figure 2 Graphs showing the release behaviors of single-layer, double-layer and triple-layer sustained-release tablets in the embodiments of the present invention.
[0032] Figure 3 is the appearance of the three-layer sustained-release tablet in the embodiment of the present invention after 1 hour in the dissolution medium, In the figure, (a) EC is the blank layer sustained-release material, (b) CMC-Na is the blank layer sustained-release material, and (c) HPMC is the blank layer sustained-release material.
[0033] Figure 4Graph showing the effect of the blank layer weight on the sustained-release behavior of the three-layer tablet in the examples of the present invention. DETAILED DESCRIPTION
[0034] The present invention is further explained below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0035] In the present invention, the specifications, materials and performances of the upper blank layer 1 and the lower blank layer 3 are consistent. In this article, upper blank layer 1 / lower blank layer 3 means that either the upper blank layer 1 or the lower blank layer 3 satisfies the corresponding characteristics.
[0036] Combined with Figure 1 It can be seen that the present invention is an NMN sustained-release tablet with a three-layer structure, with a drug-containing layer 2 in the middle, and the upper blank layer 1 is pressure-bonded to the drug-containing layer 2 on the top, and the lower blank layer 3 is pressure-bonded to the bottom. The upper blank layer 1 and the lower blank layer 3 are collectively referred to as blank layers. The degree of adhesion between the drug-containing layer 2 and the upper blank layer 1 and the lower blank layer 3 is such that the three-layer sustained-release tablet will not separate before it is completely dissolved in a weak acid or weak base environment. The function of the upper blank layer 1 and the lower blank layer 3 is to slowly dissolve in the release medium, and the drug-containing layer 2 can only slowly dissolve from the side of the sustained-release tablet to release the NMN component. The design of the upper blank layer 1 and the lower blank layer 3 reduces the contact between the upper and lower surfaces of the drug-containing layer and the release medium, thereby reducing the early burst release.
[0037] The upper blank layer 1 / lower blank layer 3 contains sustained-release material, filler and lubricant; the amount of sustained-release material is 50%-70%, preferably 60%.
[0038] The drug-containing layer 2 contains NMN, sustained-release material and filler; the NMN content of the drug-containing layer 2 is 40%-60%, preferably 50%; the amount of sustained-release material is 20%-40%, preferably 30%.
[0039] The sustained-release material is one or more of HPMC, EC, and CMC-Na, preferably HPMC K4M and HPMC K100M, which are mixed in a ratio of 1:1; the filler is one or more of MCC, starch, and dextrin, preferably MCC; and the lubricant is one or more of magnesium stearate or micro-powder silica gel.
[0040] The upper blank layer 1 / lower blank layer 3 weighs 50-200 mg, preferably 150 mg; the middle drug-containing layer 2 weighs 300-500 mg.
[0041] The diameter of the three-layer sustained-release tablet is 12.0 mm and the hardness is 50-200N.
[0042] After oral administration, the sustained-release tablet will absorb water and float, sink after floating in the stomach for a certain period of time, and then enter the intestine to continue releasing.
[0043] The following experiments are conducted to verify the sustained release effect of the three-layer sustained release tablet of the present invention and the influence of important setting factors:
[0044] Experimental data 1: Effect of multilayer structure on in vitro dissolution of sustained-release tablets
[0045] Preparation of single-layer sustained-release tablets: The prescription ingredients of the drug-containing layer were mixed and tableted to prepare a drug-containing layer with a diameter of 12.0 mm (the drug-containing layer weighed 400 mg and contained 50% of the drug).
[0046] Preparation of double-layer sustained-release tablets: Mix the prescription ingredients of the drug-containing layer, and pre-press to prepare a drug-containing layer with a diameter of 12.0 mm; mix the prescription ingredients of the blank layer, fill them on the pre-pressed drug-containing layer, and press to prepare double-layer tablets with a diameter of 12.0 mm (blank layer weighs 100 mg, drug-containing layer weighs 400 mg, and drug content is 50%), that is, pressure-bond the blank layer on the upper surface of the drug-containing layer.
[0047] Preparation of three-layer sustained-release tablets: Mix the prescription ingredients of the lower blank layer, and pre-press to prepare a lower blank layer with a diameter of 12.0 mm; mix the prescription ingredients of the drug-containing layer, fill them on the pre-pressed lower blank layer, and pre-press to prepare a double-layer tablet with a diameter of 12.0 mm; mix the prescription ingredients of the upper blank layer, fill them on the blank surface of the drug-containing layer of the pre-pressed double-layer tablet, and press to prepare a three-layer tablet with a diameter of 12.0 mm (the upper and lower blank layers weigh about 100 mg; the drug-containing layer weighs 400 mg and contains 50% of the drug), that is, pressure-bond the upper blank layer 1 and the lower blank layer 3 on both sides of the drug-containing layer.
[0048] The in vitro dissolution behavior of the three sustained-release tablets was evaluated using the paddle method with 900 mL of deionized water as the release medium. Figure 2 As shown, the single-layer sustained-release tablet released too quickly in the early stage (0-4h) (the drug release percentages at 4h and 8h were 78.3% and 99.1%, respectively); the double-layer tablet released evenly in 0-12h (the drug release percentages at 4h and 8h were 36.7% and 70.3%, respectively, and the drug release percentage at 12h was 93.0%); the three-layer tablet released evenly in 0-12h (the drug release percentages at 4h and 8h were 20.2% and 50.3%, respectively, and the drug release percentage at 12h was 82.3%).
[0049] Figure 2 The results show that compared with single-layer and double-layer sustained-release tablets, the three-layer sustained-release tablet has the slowest and most uniform drug release rate. There is no obvious burst release in the early stage of the three-layer sustained-release tablet, and the cumulative release percentage in 4 hours does not exceed 25%, and the cumulative release percentage in 8 hours does not exceed 55%. It can reduce the decline in bioavailability caused by oral absorption saturation and improve the drug's lasting properties.
[0050] Experimental data 2: Effect of the type of sustained-release material in the blank layer on the sustained-release behavior of three-layer sustained-release tablets
[0051] Preparation of three-layer sustained-release tablets: Mix the ingredients of the lower blank layer and pre-press to prepare a lower blank layer with a diameter of 12.0 mm; mix the ingredients of the drug-containing layer (add pigment for easy observation), fill it on the pre-pressed lower blank layer, and pre-press to prepare a double-layer tablet with a diameter of 12.0 mm; mix the ingredients of the upper blank layer and fill it on the blank surface of the drug-containing layer of the pre-pressed double-layer tablet, and press a three-layer tablet with a diameter of 12.0 mm (upper / lower blank layer weight 100 mg; drug-containing layer weight 400 mg, drug content 50%). The sustained-release material of the drug-containing layer is fixed to HPMC, and the effect of the type of sustained-release material of the upper / lower blank layer on the drug release behavior of the three-layer tablet is investigated.
[0052] Figure 3 The results showed that when EC was used as the sustained-release material for the upper / lower blank layers, after the three-layer tablet was added to the dissolution medium, the upper / lower blank layers were quickly separated from the drug-containing layer, and the drug-containing layer released the drug the fastest. When CMC-Na was used as the sustained-release material for the blank layer, the upper / lower blank layers dissolved too quickly, and the drug-containing layer also released the drug faster accordingly. When HPMC was used as the sustained-release material for the upper / lower blank layers, the upper / lower blank layers dissolved slowly, which was conducive to the 24h slow release of the three-layer tablet.
[0053] Experimental data 3: Effect of blank layer weight on sustained-release behavior of three-layer sustained-release tablets
[0054] Preparation of three-layer sustained-release tablets: Mix the ingredients of the upper blank layer, and pre-press to prepare a blank layer with a diameter of 12.0 mm; mix the ingredients of the drug-containing layer, fill them on the pre-pressed upper blank layer, and pre-press to prepare a double-layer tablet with a diameter of 12.0 mm; mix the ingredients of the lower blank layer, fill them on the surface of the drug-containing layer of the pre-pressed double-layer tablet, and press into a three-layer tablet with a diameter of 12.0 mm (the drug-containing layer weighs 400 mg and contains 50% of the drug).
[0055] The in vitro dissolution behavior of the three-layer tablets was evaluated using the paddle method with 900 mL of deionized water as the release medium. Figure 4As shown, when the weight of the upper / lower blank layer is 0 mg, the early stage (0-4h) release is too fast (the 4h release percentage is 78.3%). When the weight of the upper / lower blank layer is 25 mg and 50 mg, the basic drug is completely released in the middle stage (8-12h) (the 12h release percentage is 102.9% and 97.6%, respectively). When the upper / lower blank layer is 100 mg, the drug is slowly released in 0-8h (the 4h cumulative release percentage is 20.2%; the 8h cumulative release percentage is 50.3%), and most of the drug is released in the middle stage (8-12h) (the 12h release percentage is 82.3%). When the upper / lower blank layer is 150 mg, the drug is slowly released from 0 to 8 hours (the cumulative release percentage in 4 hours is 20.6%; the cumulative release percentage in 8 hours is 44.6%), and the sustained release behavior can last for 24 hours (the drug release percentage in 12 hours is 73.4%; the drug release percentage in 24 hours is 101.9%). Therefore, when the weight of the upper / lower blank layer is 150 mg, the three-layer tablet has obvious 24-hour sustained release characteristics (the drug release percentage in 4 hours does not exceed 25%; the drug release percentage in 8 hours does not exceed 50%; the drug release percentage in 12 hours does not exceed 75%).
[0056] The elderly have poor gastric motility and decreased gastrointestinal digestion and absorption functions. The sustained-release NMN tablets can ensure that the drug is slowly released in the gastrointestinal tract after oral administration, thereby improving bioavailability. The present invention discloses a three-layer sustained-release drug delivery system that can slowly release NMN for 24 hours, reduce the number of dosing times, and improve bioavailability. Compared with the prior art, the early burst release is reduced (the cumulative release percentage of 4 hours does not exceed 25%, the cumulative release percentage of 8 hours does not exceed 50%, and the cumulative release percentage of 12 hours does not exceed 75%), which can reduce the waste caused by the drug being released too quickly and not being absorbed in time, and also make the drug properties lasting and stable.
[0057] It will be understood by those skilled in the art that, unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as those generally understood by those skilled in the art to which this application belongs. It should also be understood that terms such as those defined in common dictionaries should be understood to have meanings consistent with the meanings in the context of the prior art, and will not be interpreted with idealized or overly formal meanings unless defined as herein.
[0058] Based on the above ideal embodiments of the present invention, the relevant staff can make various changes and modifications without departing from the technical concept of the present invention through the above description. The technical scope of the present invention is not limited to the contents of the specification, and its technical scope must be determined according to the scope of the claims.
[0059] The above is only a preferred embodiment of the present invention. It should be pointed out that for those skilled in the art, several improvements and modifications can be made without departing from the technical principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. An anti-aging NMN three-layer sustained-release tablet, characterized in that: The invention comprises a sheet-shaped drug-containing layer, wherein one side surface of the drug-containing layer is called the upper surface, and the other side surface is called the lower surface. The upper surface of the drug-containing layer is fully covered by an upper blank layer by pressure bonding, and the lower surface of the drug-containing layer is fully covered by a lower blank layer by pressure bonding. The upper blank layer and the lower blank layer have the same components, specifications and properties. The upper blank layer / lower blank layer contains a sustained-release material, a filler and a lubricant. The mass percentage of the sustained-release material in the upper blank layer / lower blank layer is 50%-70%. The drug-containing layer contains NMN, sustained-release material and filler; the mass percentage of NMN in the drug-containing layer is 40%-60%, and the mass percentage of sustained-release material in the drug-containing layer is 20%-40%; The sustained-release material is one or more of HPMC, EC, and CMC-Na, the filler is one or more of MCC, starch, and dextrin, and the lubricant is one or more of magnesium stearate or micro-powder silica gel.
2. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that: The mass percentage of the sustained-release material in the upper blank layer / lower blank layer is 60%.
3. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that The mass percentage of NMN in the drug-containing layer is 50%.
4. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that The mass percentage of the sustained-release material in the drug-containing layer is 30%.
5. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that The sustained-release material is HPMC.
6. The anti-aging NMN three-layer sustained-release tablet according to claim 5, characterized in that: The sustained-release materials are HPMC K4M and HPMC K100M.
7. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that: The filler is MCC.
8. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that: The diameters of the upper blank layer, the lower blank layer and the drug-containing layer are all 12.0 mm, and the hardness is 50-200N; the upper blank layer / lower blank layer weighs 50-200 mg, and the middle drug-containing layer weighs 300-500 mg.
9. The anti-aging NMN three-layer sustained-release tablet according to claim 1, characterized in that: The upper blank layer / lower blank layer weighs 150 mg; the drug-containing layer weighs 400 mg.
10. A method for manufacturing the anti-aging NMN three-layer sustained-release tablet according to any one of claims 1 to 9, characterized in that: The following steps are involved: Step (1) mixing the ingredients of the lower blank layer and pre-pressing the lower blank layer; Step (2) mixing the prescription ingredients of the drug-containing layer, filling them on the lower blank layer, and pre-pressing them to obtain a double-layer tablet; Step (3) The prescription ingredients of the upper blank layer are mixed evenly, and filled onto the blank surface of the drug-containing layer of the pre-compressed double-layer tablet obtained in step (2) to obtain a three-layer tablet.
Citation Information
Patent Citations
Nicotinamide mononucleotide sustained-release enteric orally disintegrating tablet and preparation method thereof
CN112137977A
Beta-nicotinamide mononucleotide sustained release tablet
CN112933058A
Mononucleotide sustained release tablet suitable for beta-nicotinamide
CN117180217A
